GlassScriptPhysician profile
Diane S Berson
NPI 1184655078
$42,099.79
in general payments reported to CMS, 2019-2025
20 companies · $4,946 in 2025
The $4,946 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,630 · 2021: $16K · 2022: $1,775 · 2023: $570 · 2024: $644 · 2025: $4,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,700 · Food and Beverage: $1,435 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,700.00 |
| Food and Beverage | $1,434.67 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $7,158.37 | 2019-2021 | |
| Allergan, INC. | $5,608.15 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $5,018.39 | 2019-2023 | Absorica Ld, Winlevi |
| Aclaris Therapeutics, INC. | $4,366.13 | 2019 | |
| Almirall LLC | $3,850.00 | 2019-2020 | |
| Dermira, INC. | $2,985.80 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,800.00 | 2020 | |
| Revance Therapeutics, INC. | $2,780.08 | 2024-2025 | Daxxify |
| Botanix Sb INC | $2,200.00 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $2,160.00 | 2021 | |
| Epi Health, LLC | $1,500.00 | 2022 | |
| Abbvie INC. | $642.87 | 2023-2024 | Botox, Kybella |
| Galderma Laboratories, L.P. | $479.80 | 2019-2023 | |
| Biofrontera INC. | $118.79 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $96.17 | 2025 | |
| Incyte Corporation | $76.10 | 2024 | Opzelura |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Arcutis Biotherapeutics, INC. | $57.73 | 2023 | |
| Merz North America, INC. | $25.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Berson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.